Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Author(s): Silas Ramos Furquim , Maria Tereza Sampaio de Sousa Lira , Deborah de Sá Pereira Belfort , et al Added: 2 months ago

Guidelines & Statements

Heart Failure
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added: 4 months ago Source:  Radcliffe Cardiology
Sleep-disordered breathing (SDB), a condition mediated by intermittent hypoxaemia and autonomic dysregulation, is a well-established contributor to cardiovascular morbidity. A new prospective cohort study suggests that patients with hypertrophic cardiomyopathy (HCM) are particularly at risk, revealing a high prevalence of previously undiagnosed SDB in this population. The research links the… View more

Heart Failure

Imaging & Diagnostics
ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10
Author(s): Barbara McGowan Added: 1 year ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
The Timing for Primary Prevention ICD in the Current Era of Pharmacotherapy
Author(s): Anastasia Shchendrygina , Amin Yehya , Hadi Skouri Added: 7 months ago

Heart Failure
VAC in HFpEF: Trends and Challenges
Author(s): Tianzong Li , Yiran Luo , Lina Zhao , et al Added: 2 months ago

Heart Failure

Imaging & Diagnostics
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 2 years ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 1 year ago

Heart Failure
Targeting Obesity for Heart Failure
Author(s): Emily Morris , Oliver J Rider Added: 1 month ago

Cardiovascular Renal Metabolic

Heart Failure
Pharmacological Therapy of HFrEF in 2025
Author(s): Massimo Mapelli , Filippo Maria Rubbo , Simona Costantino , et al Added: 6 months ago

Heart Failure